Role of ASCA and the NOD2/CARD15 mutation Gly908Arg in predicting increased surgical costs in Crohnʼs disease patients: A project of the European Collaborative Study Group on Inflammatory Bowel Disease

Odes, Shmuel; Friger, Michael; Vardi, Hillel; Claessens, Greet; Bossuyt, Xavier; Riis, Lene; Munkholm, Pia; Wolters, Frank; Yona, Hagit; Høie, Ole; Beltrami, Marina; Tsianos, Epameinondas V.; Katsanos, K.H.; Mouzas, Ioannis; Clofent, Juan; Monteiro, Estela; Messori, Andrea; Politi, Pierluigi; O’Moráin, Colm; Limonard, Charles; Rüssel, Maurice G.; Vatn, Morten H.; Moum, Bjørn; Stockbrügger, Reinhold W.; Vermeire, Séverine

doi:10.1002/ibd.20122

Cited by 20 publications

(12 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These data suggest a more aggressive course of the disease in carriers of risk alleles. The strongest observed effect for ileal location is consistent with the proposed involvement of ileal Paneth cells in the pathophysiology of NOD2/ CARD15-mediated disease susce ptibility [30,36,37] . NOD2/CARD15 mutations may, thus, abrogate normal Paneth cell behaviour, explaining preferential involvement of the terminal ileum [26] .…”

Section: Discussionsupporting

confidence: 81%

Clinical significance of NOD2/CARD15 and Toll-like receptor 4 gene single nucleotide polymorphisms in inflammatory bowel disease

Rigoli¹,

Romano²,

Caruso³

et al. 2008

WJG

View full text Add to dashboard Cite

nificant difference was found between UC patients and control group (P > 0.05). In CD and UC patients, no significant association with G908R variant was found. L1007finsC SNP showed an association with CD (9.8%) compared with controls (2.9%, P = 0.002) and UC patients (2.3%, P = 0.01). Moreover, in CD patients, G908R and L1007finsC mutations were significantly associated with different phenotypes compared to CD wild-type patients. No association of IBD with the TLR4 SNPs was found in either cohort (allele frequencies: D299G-controls 3.9%, CD 3.7%, UC 3.4%, P > 0.05; T399I-controls 2.9%, CD 3.0%, UC 3.4%, P > 0.05). CONCLUSION:These findings confirm that, in our IBD patients selected from Southern Italy, the NOD2/ CARD15, but not TLR4 SNPs, are associated with increased risk of CD. Abstract AIM: To evaluate the role of genetic factors in the pathogenesis of Crohn's disease (CD) and ulcerative colitis (UC), we investigated the single nucleotide polymorphisms (SNPs) of NOD2/CARD15 (R702W, G908R and L1007finsC), and Toll-like receptor 4 (TLR4) genes (D299G and T399I) in a selected inflammatory bowel disease (IBD) population coming from Southern Italy. METHODS: Allele and genotype frequencies of NOD2/ CARD15 (R702W, G908R and L1007finsC) and TLR4 (D299G and T399I) SNPs were examined in 133 CD patients, in 45 UC patients, and in 103 healthy controls. A genotype-phenotype correlation was performed. RESULTS: NOD2/CARD15 R702W mutation was significantly more frequent in CD (9.8%) than in controls (2.4%, P = 0.001) and in UC (2.3%, P = 0.03). No sig-

show abstract

Section: Discussionsupporting

confidence: 81%

Clinical significance of NOD2/CARD15 and Toll-like receptor 4 gene single nucleotide polymorphisms in inflammatory bowel disease

Rigoli¹,

Romano²,

Caruso³

et al. 2008

WJG

View full text Add to dashboard Cite

show abstract

“…7 Anti-Saccharomyces cerevisiae antibodies have been associated with complicated disease course, increased hospital costs and an increased risk of small bowel surgery in CD. [8][9][10][11][12][13] Saccharomyces cerevisiae is an ascomycetous yeast extensively used in the brewing and baking industry. 14 Therefore, the human alimentary tract is widely exposed to its antigens.…”

Section: Discussionmentioning

confidence: 99%

The impact of intestinal resection on serum levels of anti‐Saccharomyces cerevisiae antibodies (ASCA) in patients with Crohn’s disease

Eser

Papay

Primas

et al. 2011

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…As a third type of Bbiomarker,^genetic risk factors may be seen because they also have some predictive value for the course of IBD (especially in Crohn's disease) and potentially also for relapse rates [33,[52][53][54][55]. (Genetic) biomarkers for the prediction of the response to therapy are almost only available in the context of azathioprine and 6-mercaptopurine therapy [56][57][58].…”

Section: Introductionmentioning

confidence: 99%

Clinical Utility of Biomarkers in IBD

Rogler

Biedermann

2015

Curr Gastroenterol Rep

View full text Add to dashboard Cite

There is no gold standard for the diagnosis and monitoring of inflammatory bowel diseases (IBD). Biomarkers are useful tools for the management of patients suffering from IBD. However, they should be used only when their additional information is useful for clinical decision-making. In principal, four situations during the management of an individual IBD patient can be discriminated from a clinical standpoint in which biomarkers provide useful information. First, biomarkers may be helpful when the diagnosis of IBD is established and aid in the discrimination between ulcerative colitis (UC) and Crohn's disease (CD) is necessary. Second, biomarkers may be helpful in the prognostic evaluation of IBD severity or disease behavior and for early decisions on the best treatment. The third situation in which biomarkers are useful is the evaluation of disease activity during the disease course, for monitoring and for guidance of ongoing treatment. Finally, the fourth typical situation when biomarkers are of value is after surgery to predict or diagnose a relapse of the disease. From a clinical point of view, it may be more useful to discuss specific biomarkers and their individual value and impact in these four prototypic situations than to sum up advantages and disadvantages for each biomarker isolated from the clinical situation. Therefore, this overview is structured in chapters reflecting those four typical situations during the disease course of IBD patents to critically evaluate the potential and value of each of the biomarkers in the specific situation.

show abstract

Role of ASCA and the NOD2/CARD15 mutation Gly908Arg in predicting increased surgical costs in Crohnʼs disease patients: A project of the European Collaborative Study Group on Inflammatory Bowel Disease

Abstract: Since CD patients positive for Gly908Arg and ASCA demonstrated higher health care costs, it is possible that measurement of Gly908Arg and ASCA at disease diagnosis can forecast the expensive CD patients.

Cited by 20 publications

References 33 publications

Clinical significance of NOD2/CARD15 and Toll-like receptor 4 gene single nucleotide polymorphisms in inflammatory bowel disease

Clinical significance of NOD2/CARD15 and Toll-like receptor 4 gene single nucleotide polymorphisms in inflammatory bowel disease

The impact of intestinal resection on serum levels of anti‐Saccharomyces cerevisiae antibodies (ASCA) in patients with Crohn’s disease

Clinical Utility of Biomarkers in IBD

Contact Info

Product

Resources

About